Quattro Financial Advisors LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Quattro Financial Advisors LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 3,480 shares of the company’s stock, valued at approximately $299,000.

A number of other institutional investors have also recently made changes to their positions in the business. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S in the third quarter worth $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at about $42,000. Albion Financial Group UT raised its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the period. Finally, Hager Investment Management Services LLC acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.9 %

Novo Nordisk A/S stock opened at $86.39 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The stock has a market capitalization of $387.66 billion, a PE ratio of 26.26, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The business has a 50 day simple moving average of $91.86 and a 200-day simple moving average of $111.83. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.